Literature DB >> 12894076

Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice.

Adam A Pettey1, Rajesh Balkrishnan, Stephen R Rapp, Alan B Fleischer, Steven R Feldman.   

Abstract

BACKGROUND: Psoriasis is a chronic, unpredictable, and incurable disease that has a negative impact on patients' quality of life. Palm and sole psoriasis can add to this negative impact as it directly affects activities of daily living.
OBJECTIVE: We sought to estimate the prevalence of palmoplantar psoriasis in a patient population and to explore associations with patient outcomes.
METHODS: In all, 317 individuals with psoriasis completed a comprehensive assessment battery. Patients with palmoplantar psoriasis (n = 124, 39%) were compared with patients without palmoplantar involvement with respect to functional disability, psychiatric symptoms, physical and social discomfort, self-reported psoriasis severity, and health-related quality of life.
RESULTS: Patients with palmoplantar involvement reported significantly greater physical disability and physical discomfort than patients without palmoplantar involvement (both P <.01). There were no differences between the 2 groups with respect to psychosocial outcomes.
CONCLUSION: Patients with palmoplantar psoriasis are affected to a greater degree by the physical aspects of the disease than patients without palmoplantar involvement.

Entities:  

Mesh:

Year:  2003        PMID: 12894076     DOI: 10.1067/s0190-9622(03)01479-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  28 in total

1.  Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.

Authors:  Peter Foley; Kenneth Gordon; Christopher E M Griffiths; Yasmine Wasfi; Bruce Randazzo; Michael Song; Shu Li; Yaung-Kaung Shen; Andrew Blauvelt
Journal:  JAMA Dermatol       Date:  2018-06-01       Impact factor: 10.282

Review 2.  Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.

Authors:  April W Armstrong; Ron Vender; Leon Kircik
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01

3.  Rapid improvement of palmoplantar psoriasis after cessation of smoking.

Authors:  Husein H Elahmed
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

4.  Targeted phototherapy using 308 nm Xecl monochromatic excimer laser for psoriasis at difficult to treat sites.

Authors:  Nawaf Al-Mutairi; Ahmad Al-Haddad
Journal:  Lasers Med Sci       Date:  2012-09-28       Impact factor: 3.161

5.  UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study.

Authors:  Li-Na Su; Jie Ren; Shi-Meng Cheng; Jian-Lan Liu; Yang-Feng Ding; Ning-Wen Zhu
Journal:  Lasers Med Sci       Date:  2017-07-11       Impact factor: 3.161

6.  Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.

Authors:  Jina Chung; Kristina Callis Duffin; Junko Takeshita; Daniel B Shin; Gerald G Krueger; Andrew D Robertson; Andrea B Troxel; Abby S Van Voorhees; Emily Edson-Heredia; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2014-06-02       Impact factor: 11.527

7.  Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.

Authors:  Tadashi Terui; Satomi Kobayashi; Yukari Okubo; Masamoto Murakami; Keiichiro Hirose; Hiroshi Kubo
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

8.  Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.

Authors:  Emese Herédi; Fanni Rencz; Orsolya Balogh; László Gulácsi; Krisztina Herszényi; Péter Holló; Hajnalka Jókai; Sarolta Kárpáti; Márta Péntek; Éva Remenyik; Andrea Szegedi; Valentin Brodszky
Journal:  Eur J Health Econ       Date:  2014-05-16

9.  Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial.

Authors:  Andreas Katsambas; Ketty Peris; Gino Vena; Peter Freidmann; Gottfried Wozel; Esteban Daudén; Daiana Licu; Mauro Placchi; Michel De La Brassinne
Journal:  Arch Drug Inf       Date:  2009-12

10.  A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.

Authors:  Bruce E Strober; Jennifer Clay Cather; David Cohen; Jeffrey J Crowley; Kenneth B Gordon; Alice B Gottlieb; Arthur F Kavanaugh; Neil J Korman; Gerald G Krueger; Craig L Leonardi; Sergio Schwartzman; Jeffrey M Sobell; Gary E Solomon; Melodie Young
Journal:  Dermatol Ther (Heidelb)       Date:  2012-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.